CTOs on the Move

Park Surgical

www.parksurgical.com

 
Park Surgical is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

DirectDME

We help reduce the costs and administration of providing durable medical equipment for: Employers / Self-Insureds Insurance carriers Workers' compensation claims processors Case management service companies Third party administrators (TPAs)

VisCardia

VisCardia Inc is a privately held medical device company in Portland Oregon developing a novel chronic heart failure therapy. Our proprietary implantable system uses the patient’s own thoracic musculature to improve cardiac filling and output.

Brijjitco

The Brijjit™ technology is created and produced by BrijjitCo, a limited liability company based in Atlanta, GA.. Our founder and CEO, Felmont (Monte) F. Eaves, III, MD, FACS, is a highly credentialed plastic surgeon who saw a gap and was determined to bridge it. No, we`re not a huge company. Yet. But we are singularly focused on improving the surgical landscape with breakthrough technologies that will support surgeons everywhere in their goal to deliver the most spectacular outcomes. We strongly believe that Brijjit™ is just such an innovation, and we don`t plan to stop there!

MJS BioLynx

MJS BioLynx Inc. is a Brockville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GT Medical Technologies

Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This "one-and-done" treatment eliminates the need for one to six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 95 hospitals, with more centers being added each month.